Lipocine (NASDAQ:LPCN) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Lipocine Inc. (NASDAQ:LPCN)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.64 and traded as low as $2.26. Lipocine shares last traded at $2.26, with a volume of 55,639 shares trading hands.

Wall Street Analysts Forecast Growth

LPCN has been the subject of several recent analyst reports. Wall Street Zen cut shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. HC Wainwright reissued a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Lipocine presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Lipocine Stock Performance

The company has a market cap of $18.62 million, a PE ratio of -1.20 and a beta of 0.50. The stock’s 50 day moving average price is $4.48 and its 200-day moving average price is $5.64.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.16 million. On average, analysts anticipate that Lipocine Inc. will post -1.91 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Mahesh V. Patel purchased 25,000 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was bought at an average cost of $2.03 per share, for a total transaction of $50,750.00. Following the acquisition, the chief executive officer directly owned 160,679 shares of the company’s stock, valued at $326,178.37. This represents a 18.43% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director John W. Higuchi purchased 40,000 shares of the stock in a transaction that occurred on Tuesday, April 7th. The shares were purchased at an average price of $2.03 per share, with a total value of $81,200.00. Following the completion of the acquisition, the director directly owned 203,797 shares in the company, valued at $413,707.91. The trade was a 24.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 213,000 shares of company stock valued at $434,600 over the last quarter. 6.35% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Lipocine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC purchased a new stake in Lipocine during the 3rd quarter valued at about $41,000. Jane Street Group LLC bought a new position in shares of Lipocine in the 4th quarter worth approximately $85,000. Dimensional Fund Advisors LP lifted its stake in shares of Lipocine by 57.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares during the period. Renaissance Technologies LLC lifted its holdings in Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in Lipocine during the fourth quarter valued at approximately $441,000. 9.11% of the stock is currently owned by institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.